Psilocybin-Research.comSearchable psilocybin and psilocin bibliometrics.
PREPRINT (not peer reviewed)

Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD

Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction. However, no studies have examined whether acute subjective experiences predict treatment response in obsessive-compulsive disorder (OCD). Methods: Exploratory analyses were conducted using data from participants with treatment-resistant OCD who received psilocybin as part of a randomized, double-blind, placebo-controlled trial and subsequent open-label phase. Twenty-seven participants who received psilocybin (0.25 mg/kg) completed the Mystical Experience Questionnaire (MEQ) and Challenging Experience Questionnaire (CEQ) the day following their session. OCD severity was assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and at 1- and 12-week follow-up. Results: Greater mystical-type experiences during psilocybin were associated with lower OCD symptom severity at 1- and 12-week follow-up, even after controlling for baseline OCD symptom severity and treatment condition. The Mystical subscale demonstrated the strongest and most consistent associations at both time points, while the Space-Time subscale was only associated with lower Y-BOCS at 12 weeks. The Positive Mood and Ineffability subscales were not significantly associated with post-treatment OCD symptom severity after correction for multiple comparisons. Challenging experiences were not significantly associated with post-treatment OCD severity. Conclusions: Mystical experiences - particularly experiences of unity, sacredness, and transcendence - during psilocybin sessions are associated with greater OCD symptom reduction. These findings support attention to experiential quality in psilocybin-assisted therapy and have implications for optimizing treatment through dosing, set, setting, and integration practices.

Open source BibTeX RIS

Bibliographic context

Journal
PsyArXiv
Date
2026-02-10
Source
PsyArXiv
DOI
Unavailable
PubMed
Unavailable

Authors

Watch author

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical ImplicationsFOCUS The Journal of Lifelong Learning in Psychiatry · 2026-03-31Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulationsPsychiatry and Clinical Neurosciences · 2026-02-25Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trialGeneral Hospital Psychiatry · 2025-08-11Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étudeThe Canadian Journal of Psychiatry · 2025-03-24Enlightenment in a Pill-Testing the Efficacy of PsilocybinJAMA Psychiatry · 2026-03-17Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamineGeneral Hospital Psychiatry · 2026-02-24Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxietyGeneral Hospital Psychiatry · 2025-12-08Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreatFrontiers in Psychiatry · 2025-08-05